Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2017 | Necitumumab plus pembrolizumab: a viable alternative for NSCLC

Benjamin Besse, MD, PhD, from the Gustave Roussy Cancer Institute, Paris, France, discusses a recent study he authored at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. This study (NCT02451930) investigated the efficacy of pembrolizumab plus necitumumab in a cohort of approximately 64 patients, half with squamous histology, half with non-squamous. The toxicity of the combination is more severe than the individual agents, however, the combination appeared to be well tolerated. Despite this, the response rate wasn’t high enough to proceed investigations with this combination.